Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
psilocybin
Biotech
Psyence acquires fellow psilocybin biotech Clairvoyant
Psyence Biomedical is paying $500,000 in shares to acquire Clairvoyant Therapeutics and its phase 2-stage alcohol use disorder candidate.
James Waldron
Sep 6, 2024 9:25am
Compass tracks PTSD improvements in midphase psilocybin trial
May 8, 2024 8:07am
Reunion nets $103M, one of the largest for a psychedelic biotech
May 2, 2024 6:30am
Compass, Hackensack Meridian ink research deal for psilocybin
Jan 17, 2024 10:53am
Compass shows safety in first psilocybin trial for PTSD
Dec 20, 2023 7:26am
Investors unenthused by Cybin's latest ph. 2 depression data
Nov 30, 2023 9:25am